Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Testosterone Deficiency Clear all
Completed Phase 2 Interventional

A Study of Megestrol Acetate Alone or in Combination With Testosterone Enanthate Drug in the Treatment of HIV-Associated Weight Loss

NCT00001079
View directory record Official record
Conditions
HIV Infections, HIV Wasting Syndrome
Interventions
Testosterone enanthate, Megestrol acetate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
21
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 22, 2026, 10:45 AM EDT
Active, not recruiting Phase 2 Interventional

Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency

NCT04301765
View directory record Official record
Conditions
Hypogonadism, Male, Cancer, Fatigue
Interventions
testosterone 1.62% gel, placebo gel
Drug · Other
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
55 Years and older · Male only
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Augusta, Georgia • Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 22, 2026, 10:45 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males

NCT03335254
View directory record Official record
Conditions
Hypogonadism, Hypogonadism, Male, Gonadal Disorders, Endocrine System Diseases, Testosterone Deficiency
Interventions
TSX-011
Drug
Lead sponsor
TesoRx Pharma, LLC
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

TDSM- Testosterone Dose Response in Surgically Menopausal Women

NCT00494208
View directory record Official record
Conditions
Hysterectomy, Ovariectomy, Menopause, Testosterone Deficiency
Interventions
Testosterone
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
21 Years to 60 Years · Female only
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 30, 2013 · Synced Jul 22, 2026, 10:45 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Baseline Sexual Function, Cognitive Function, Body Composition and Muscle Parameters and Pharmacokinetics of Transdermal Testosterone Gel in Women With Hypopituitarism

NCT00144404
View directory record Official record
Conditions
Panhypopituitarism
Interventions
Not listed
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years to 55 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Study to Determine the Effects of Testosterone Replacement Therapy in Aging Men With Androgen Deficiency

NCT00161304
View directory record Official record
Conditions
Men With Low Testosterone Levels
Interventions
Testosterone Enanthate, Placebo
Drug · Other
Lead sponsor
Leonard S. Marks, M.D.
Other
Eligibility
50 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Jul 22, 2026, 10:45 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Use of Infrared Photomodulation for Hormonal Balance (Joovvin' for Hormonal Health)

NCT04245527
View directory record Official record
Conditions
Testosterone Deficiency, Estrogen Deficiency
Interventions
Joovv Infrared Light Device
Device
Lead sponsor
ProofPilot
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Jul 22, 2026, 10:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Metabolomics During Testosterone Therapy

NCT01963390
View directory record Official record
Conditions
Testosterone Deficiency
Interventions
Testosterone Therapy
Drug
Lead sponsor
Men's Health Boston
Other
Eligibility
20 Years to 90 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

Testosterone and Growth Hormone for Bone Loss in Men

NCT00080483
View directory record Official record
Conditions
Hypopituitarism, Hypogonadism, Growth Hormone Deficiency
Interventions
Testosterone plus somatropin, testosterone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 12, 2014 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 4 Interventional

Testosterone for HIV-Positive Men With Reduced Serum Testosterone Levels and Abdominal Fat

NCT00009555
View directory record Official record
Conditions
HIV Infections
Interventions
Testosterone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years · Male only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
26
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 2 Interventional

28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men

NCT00398580
View directory record Official record
Conditions
Hypogonadism, Hypogonadism, Male
Interventions
Nanomilled testosterone, Nanomilled dutasteride, commercially available dutasteride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
Torrance, California • Louisville, Kentucky • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 3 Interventional

Bioequivalence Study of Test and Reference Testosterone Topical Gel, 1.62% Metered Pump in Testosterone Deficient Adult Male Subjects Under Fasting Conditions

NCT02110368
View directory record Official record
Conditions
Primary Hypogonadism, Hypogonadotropic Hypogonadism
Interventions
Testosterone Topical Gel, 1.62% Metered Pump, AndroGel (testosterone gel) 1.62% Metered-Dose Pump
Drug
Lead sponsor
Amneal Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Miami Gardens, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 4 Interventional Results available

Subcutaneous vs. Intramuscular Testosterone

NCT03091348
View directory record Official record
Conditions
Testosterone Deficiency, Hypogonadism, Male
Interventions
Testosterone
Drug
Lead sponsor
Men's Health Boston
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Jul 22, 2026, 10:45 AM EDT
Recruiting Phase 3 Interventional

52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism

NCT06689085
View directory record Official record
Conditions
Hypogonadism, Male
Interventions
Testosterone enanthate
Combination Product
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
12 Years to 17 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
20
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Jul 22, 2026, 10:45 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Does Testosterone Therapy Improve Patient-Reported Outcomes in Age-Related Testosterone Deficient Patients Undergoing Total Hip Replacement: A Randomized-Controlled Trial

NCT05722301
View directory record Official record
Conditions
Arthroplasty, Replacement, Hip
Interventions
Testosterone Therapy, No Testosterone Therapy
Drug · Other
Lead sponsor
American Hip Institute
Other
Eligibility
50 Years and older · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Des Plaines, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Testosterone Gel Applied to Women With Pituitary Gland Problems

NCT00144391
View directory record Official record
Conditions
Panhypopituitarism
Interventions
Transdermal Testosterone gel
Drug
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

Time to Eugonadal Range, Time to Steady State and Drying Time

NCT01228071
View directory record Official record
Conditions
Male Hypogonadism
Interventions
testosterone gel 2%
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
Tucson, Arizona • Middlebury, Connecticut • Oviedo, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Jul 22, 2026, 10:45 AM EDT
Withdrawn Early Phase 1 Interventional

Androgen Regulation of Priapism in Sickle Cell Disease

NCT01940718
View directory record Official record
Conditions
Priapism, Sickle Cell Disease, Hypogonadism
Interventions
Transdermal Androgel
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Jul 22, 2026, 10:45 AM EDT
Completed No phase listed Observational

Use of a Test That Evaluates How the Body Handles Insulin and Glucose

NCT00027092
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Honolulu, Hawaii + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2008 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 2 Interventional

Phase II Randomized Study of Physiologic Testosterone Replacement in Premenopausal, HIV-Positive Women

NCT00004400
View directory record Official record
Conditions
HIV Infections, Cachexia
Interventions
testosterone
Drug
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
3
States / cities
Los Angeles, California • Torrance, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride

NCT00400335
View directory record Official record
Conditions
Hypogonadism, Hypogonadism, Male
Interventions
Nanomilled testosterone, commercially available dutasteride, Nanomilled dutasteride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 3, 2012 · Synced Jul 22, 2026, 10:45 AM EDT
Recruiting No phase listed Observational

Testosterone Deficiency and Endothelial Dysfunction After Spinal Cord Injury

NCT07227740
View directory record Official record
Conditions
Spinal Cord Injuries, Endothelial Dysfunction, Testosterone Deficiency
Interventions
Intra-arterial Infusion of Vasoactive Agents, Intra-arterial Vitamin C Infusion, Blood Sampling
Diagnostic Test
Lead sponsor
Craig Hospital
Other
Eligibility
18 Years to 89 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 3 Interventional

Open-Label Study of ARD-0403 in Testosterone Deficient Men

NCT00448955
View directory record Official record
Conditions
Hypogonadism
Interventions
ARD-0403
Drug
Lead sponsor
Ardana Bioscience Ltd
Industry
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
12
States / cities
Huntsville, Alabama • Stanford, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2008 · Synced Jul 22, 2026, 10:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Transdermal Testosterone Gel/Effect on Erection Quality as Measured by DIR

NCT00425568
View directory record Official record
Conditions
Hypogonadism
Interventions
AndroGel (Transdermal Testosterone Gel)
Drug
Lead sponsor
Lamm, Steven, M.D.
Individual
Eligibility
21 Years to 59 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Jul 22, 2026, 10:45 AM EDT